Overview

Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:
All

Summary

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Cyclosporine
Cyclosporins

Criteria

Inclusion Criteria:

- Recipient of first time kidney transplant

- Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

- Recipient of any non-kidney transplant